NAMS CEO Buys As CSO Cashes Out Before PREVAIL Risk
NewAmsterdam Pharma's CEO made the only open-market insider purchase in three months while his Chief Scientific Officer sold $4.6 million in the same window — and the stock has since fallen below the
NAMS CEO Buys As CSO Cashes Out Before PREVAIL Risk
NEW YORK, October 14 —
When NewAmsterdam Pharma Company N.V. (NAMS) CEO Michael Davidson paid $22.65 per share in the period's only insider open-market purchase, his Chief Scientific Officer sold $4.62 million across two transactions in the same 90-day window. The stock has since fallen to $20.09, leaving Davidson underwater as RBC labels PREVAIL Phase 3 interim risk "considerable."
- CEO Davidson bought 10,000 shares at $22.65 on Sept. 14; the stock now trades at $20.09, below his entry.
- CSO Kastelein sold $4.62 million across two option-exercise-and-sell transactions; net 90-day insider activity: $0.23M bought, $7.85M sold.
- NAMS holds $630 million in cash against zero debt; RBC flagged "considerable" risk on the upcoming PREVAIL Phase 3 interim.
Opposite Trades From the Same Clinical Read
NewAmsterdam Pharma Company N.V. is a pre-commercial Dutch biotech whose sole asset, Obicetrapib, is an oral CETP inhibitor targeting LDL-C reduction in cardiovascular disease patients, currently in Phase 3 trials with no approved products. Davidson's September 14 open-market purchase of 10,000 shares, deploying $226,500, was the period's only insider buy. Kastelein's two transactions were option-exercise-and-sell: $3.36 million exiting August 24 at $26.91 per share, then $1.26 million more on September 30 at $25.03, sixteen days after Davidson's purchase and one day after NAMS filed an 8-K under Item 8.01.
Why PREVAIL Is the Only Number That Matters
The entire $2.40 billion market capitalization is an option on PREVAIL. NAMS has $630 million in cash against zero debt and $143 million in annual operating outflows, roughly four years of runway, but no approved drugs and no real revenue. RBC assessed the Phase 3 interim as facing "considerable" risk in an October 5 report. Obicetrapib is also being evaluated in a Phase 2a Alzheimer's disease trial, and an October 10 report flagged the SPINOZA trial start as a potential catalyst, though PREVAIL remains the nearer binary and the one both executives were pricing when they moved in opposite directions.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| NAMS | $2.4B | n/a | -50.1% |
| MLYS | $1.9B | n/a | -51.6% |
| EWTX | $4.1B | n/a | +132.3% |
| IRON | $2.2B | n/a | -26.5% |
| ELVN | $2.9B | n/a | +81.7% |
| DNTH | $4.1B | n/a | +114.3% |
All Insider Exits Now Trade Above Market
At $20.09, NAMS trades below Davidson's purchase price, below Kastelein's $25.03 September exit, and well below CAO Louise Kooij's July sales at $29.96 to $31.71. A DCF calculator offers limited traction on a pre-revenue biotech; the consensus analyst target of $49.42, implying 146% upside from current levels, works less as a valuation anchor than a probability-weighted clinical bet on PREVAIL passing. Short interest at 18.6% of the float captures the opposing view. The PREVAIL interim read is the single number that resolves the Davidson-Kastelein divergence: a positive signal validates the CEO's lone purchase; a miss confirms the exits. Run the free NewAmsterdam Pharma Company N.V. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
NewAmsterdam Pharma's CEO made the only open-market insider purchase in three months while his Chief Scientific Officer sold $4.6 million in the same window — and the stock has since fallen below the CEO's entry price as RBC flags 'considerable' risk on the PREVAIL Phase 3 interim analysis.